Q2 2024
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | Mineralys Therapeutics, Inc. | $107,576,574 | – | 9,194,579 | – | 81.19% | – | |
| New | HilleVax, Inc. | $17,481,764 | – | 1,208,974 | – | 13.19% | – | |
| PHAT | New | Phathom Pharmaceuticals, Inc. | $7,436,208 | – | 721,962 | – | 5.61% | – |
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | Mineralys Therapeutics, Inc. | $107,576,574 | – | 9,194,579 | – | 81.19% | – | |
| New | HilleVax, Inc. | $17,481,764 | – | 1,208,974 | – | 13.19% | – | |
| PHAT | New | Phathom Pharmaceuticals, Inc. | $7,436,208 | – | 721,962 | – | 5.61% | – |